Novavax Stock Fair Value Calculation – Novavax Annual Meeting Postponed Due to Lack of Quorum
June 16, 2023
🌧️Trending News
Novavax ($NASDAQ:NVAX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases, recently announced that its annual meeting has been postponed due to a lack of quorum. Originally scheduled for June, the meeting has been pushed until July and requires a majority of shareholders to be in attendance in order to move forward with the meeting. Novavax is best known for its work on a vaccine for the novel coronavirus, which is currently in clinical trials around the world. The company has also recently launched a range of other vaccines, including a flu vaccine and a vaccine for the MERS virus.
The postponement of the annual meeting may come as a disappointment to shareholders as it is an important event that allows them to vote on important matters such as approving the compensation of senior management and any changes to the company’s bylaws. Despite the delay, Novavax is still expected to meet its current timelines for the completion of its clinical trials.
Price History
On Thursday, Novavax announced the postponement of its annual meeting due to a lack of quorum. Despite the news, Novavax stock opened at $7.7 and closed at $8.1, an increase of 4.4% from its previous closing price. The company stated that it would reschedule its annual meeting at a later date and inform shareholders of the new date and time when available. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Novavax. More…
| Total Revenues | Net Income | Net Margin |
| 1.37k | -1.16k | -84.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Novavax. More…
| Operations | Investing | Financing |
| -653.02 | -99.72 | -189.26 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Novavax. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.54k | 2.44k | -10.38 |
Key Ratios Snapshot
Some of the financial key ratios for Novavax are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 323.4% | – | -82.7% |
| FCF Margin | ROE | ROA |
| -54.9% | 92.6% | -45.9% |
Analysis – Novavax Stock Fair Value Calculation
GoodWhale has analyzed the financials of NOVAVAX and found that its intrinsic value is around $148.5, as calculated by our proprietary Valuation Line. This means that compared to the current share price of $8.1, NOVAVAX is currently undervalued by an incredible 94.5%. This could be an excellent opportunity for investors to purchase shares in this undervalued company. We believe that investing in NOVAVAX stock could be a wise move for investors, as it has potential for great returns. Therefore, we suggest that investors take this opportunity to purchase NOVAVAX shares while they are still undervalued. Novavax_Annual_Meeting_Postponed_Due_to_Lack_of_Quorum”>More…
Peers
The competition between Novavax Inc and its competitors is fierce. Moderna Inc, BioNTech SE, and Pfizer Inc are all major players in the vaccine industry, and each company is striving to develop the most effective vaccine possible. While Novavax Inc has made great strides in recent years, its competitors are not far behind.
– Moderna Inc ($NASDAQ:MRNA)
Moderna Inc is a clinical stage biotechnology company that discovers, develops, and commercializes therapeutics and vaccines based on RNA. As of 2022, Moderna Inc has a market cap of 48.32B and a ROE of 80.28%. Moderna Inc’s mission is to harness the power of RNA to revolutionize medicine and change the way diseases are prevented, treated, and cured.
– BioNTech SE ($NASDAQ:BNTX)
As of 2022, BioNTech SE has a market cap of 32.44B and a Return on Equity of 71.82%. The company is a German biotechnology company that develops and manufactures vaccines and antibody therapeutics. The company has developed a platform that allows it to rapidly design and produce custom-made vaccines and therapeutics.
– Pfizer Inc ($NYSE:PFE)
Pfizer Inc is a pharmaceutical company with a market cap of 247.45B as of 2022. The company has a return on equity of 24.63%. Pfizer Inc is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets safe, effective, and affordable human and veterinary medicines. The company is one of the world’s largest research-based pharmaceutical companies, with products available in more than 150 countries.
Summary
Investing in Novavax can be a lucrative opportunity for investors. This is a positive sign, as it shows investors are confident in the company’s future success and progress. Furthermore, Novavax has been steadily increasing revenue over the past year, while also continuing to develop new products and services that could benefit investors. All of these factors combined make it an attractive option for investors who are looking to add a quality company to their portfolio.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
